CUSIP: 75973T101
Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / ADS
-
Total 13F shares
-
4,492,705
-
Share change
-
+925,282
-
Total reported value
-
$7,187,581
-
Put/Call ratio
-
404%
-
Price per share
-
$1.60
-
Number of holders
-
26
-
Value change
-
+$1,425,380
-
Number of buys
-
15
-
Number of sells
-
12
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2023
-
Previous quarter:
Q2 2023
Recent filing periods for CUSIP 75973T101:
Institutional Holders of Renalytix plc - ADS (RNLXY) as of Q3 2023
As of 30 Sep 2023,
Renalytix plc - ADS (RNLXY) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,492,705 shares.
The largest 10 holders included
GILDER GAGNON HOWE & CO LLC, PINNACLE ASSOCIATES LTD, Pentwater Capital Management LP, Tejara Capital Ltd, Allspring Global Investments Holdings, LLC, Corient Private Wealth LLC, Granahan Investment Management, LLC, CVI Holdings, LLC, LAZARD ASSET MANAGEMENT LLC, and JPMORGAN CHASE & CO.
This page lists
26
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.